A new negative regulator of autophagy in cellular and organismal homoeostasis
Lead Research Organisation:
University of Edinburgh
Department Name: Edinburgh Cancer Research Centre
Abstract
During life, mammals have to keep their bodies and minds in a state of constancy, as much as possible, despite all sorts of challenges. For example, animals are exposed to periods without regular food, with inadvertent exposure to infectious bacteria, and with all sorts of insults that contribute to faster ageing, and the decline of important organs and of cognitive abilities. In the latter examples this includes the accumulation of damaged cellular components, e.g. proteins (including so-called 'unfolded' proteins that have the wrong shape and can stick to each other, forming toxic deposits) and other, larger cellular components, often composed of many hundreds of types of proteins and other molecules (e.g. 'organelles'). Given this, it is remarkable how well mammalian physiology copes with these problems. We refer to maintenance of this "constant state" as homeostasis.
In the applicant's lab, we study a process called autophagy. This is a system for disposing of unwanted components of cells in packets ('garbage bags') called autophagosomes - for example the damaged proteins and organelles referred to above - and other garbage - such as bacteria infecting individual cells (such as occurs, for example, in the lining of the gut on Salmonella infection). Autophagy operates in virtually all bodily tissues. Autophagy famously goes awry in certain diseases, e.g cancer, inflammation, neurodegeneration. However, it has become increasingly clear that autophagy plays a major role in homeostasis, i.e. the maintenance of the normal state of cells in animals, and thus the animal as a whole. Animals require autophagy to fight bacterial infection, prevent ageing-related decline of bodily organs and brain functions. Autophagy also has a neat dual function - the 'garbage' can provide energy and building blocks when it is broken down to keep the cells alive when nutrients are short (as occurs during e.g. fasting). Thus animals also require autophagy to bridge gaps in food intake/usage. However, too much autophagy can also be damaging to cells. To this end, cells control the amount of autophagy carefully, although recent studies show that modestly enhanced autophagy could improve homeostatic outcomes, particularly during ageing.
We propose to provide new information on how this autophagy pathway is controlled. We think we have identified a gene that slows down the autophagy process. By testing this idea, by studying at a very detailed molecular level how this gene (CCPG1) acts in cells, and discovering how it impacts on nutrient/metabolic responses and ageing in mice, we hope to both a) cast new light on mechanisms by which this important pathway of autophagy works in cells and b) discover a new gene that - via its link to autophagy - controls important homeostatic outcomes in adult and ageing animals (relevant to mammalian biology, including livestock and human health). This work may subsequently lead to future research proposal to find ways to manipulate the function of this gene to control autophagy and improve homoeostasis.
We will use standard cell biology technique and biochemical techniques that will allow us to see how the product of the CCPG1 gene associates with and directs the interplay of known molecules that drive the process of autophagy. However, we will also use some cutting-edge microscopy techniques (electron microscopic and so-called 'super-resolution' light microscopic) to gain unprecedented insight into how known molecules in the autophagy pathway are being orchestrated. However, it is difficult to know how relevant effects we see in isolated cells are in a whole animal, where many millions of cells interact in complicated organ systems. So, we have made a mouse deficient in CCPG1. We aim to show that homeostatic functions, particularly during ageing or fasting, are different in these mice.
In the applicant's lab, we study a process called autophagy. This is a system for disposing of unwanted components of cells in packets ('garbage bags') called autophagosomes - for example the damaged proteins and organelles referred to above - and other garbage - such as bacteria infecting individual cells (such as occurs, for example, in the lining of the gut on Salmonella infection). Autophagy operates in virtually all bodily tissues. Autophagy famously goes awry in certain diseases, e.g cancer, inflammation, neurodegeneration. However, it has become increasingly clear that autophagy plays a major role in homeostasis, i.e. the maintenance of the normal state of cells in animals, and thus the animal as a whole. Animals require autophagy to fight bacterial infection, prevent ageing-related decline of bodily organs and brain functions. Autophagy also has a neat dual function - the 'garbage' can provide energy and building blocks when it is broken down to keep the cells alive when nutrients are short (as occurs during e.g. fasting). Thus animals also require autophagy to bridge gaps in food intake/usage. However, too much autophagy can also be damaging to cells. To this end, cells control the amount of autophagy carefully, although recent studies show that modestly enhanced autophagy could improve homeostatic outcomes, particularly during ageing.
We propose to provide new information on how this autophagy pathway is controlled. We think we have identified a gene that slows down the autophagy process. By testing this idea, by studying at a very detailed molecular level how this gene (CCPG1) acts in cells, and discovering how it impacts on nutrient/metabolic responses and ageing in mice, we hope to both a) cast new light on mechanisms by which this important pathway of autophagy works in cells and b) discover a new gene that - via its link to autophagy - controls important homeostatic outcomes in adult and ageing animals (relevant to mammalian biology, including livestock and human health). This work may subsequently lead to future research proposal to find ways to manipulate the function of this gene to control autophagy and improve homoeostasis.
We will use standard cell biology technique and biochemical techniques that will allow us to see how the product of the CCPG1 gene associates with and directs the interplay of known molecules that drive the process of autophagy. However, we will also use some cutting-edge microscopy techniques (electron microscopic and so-called 'super-resolution' light microscopic) to gain unprecedented insight into how known molecules in the autophagy pathway are being orchestrated. However, it is difficult to know how relevant effects we see in isolated cells are in a whole animal, where many millions of cells interact in complicated organ systems. So, we have made a mouse deficient in CCPG1. We aim to show that homeostatic functions, particularly during ageing or fasting, are different in these mice.
Technical Summary
Autophagy is a trafficking pathway that transports cytosol to the lysosome, in vesicles called autophagosomes. This is vital in animal homeostasis. Cytosol can be degraded to provide energy during periods of fasting. Degrading damaged proteins and organelles defends against cognitive and corporeal decline (ageing). Autophagy can also target infectious cytosolic bacteria.
Progress has been made unpicking the 'core' mechanism of autophagy. However, regulatory pathways are less well defined; particularly specific negative regulators. Other outstanding questions include a) the regulation of a protein complex called ULK (includes the scaffold, FIP200, and ULK protein kinase) and b) understanding how a site for autophagosome generation, the ER-localised omegasome, can specify the composition of autophagosomes. Here we propose a new negative regulator of autophagy, a little-studied single-pass transmembrane protein, specific to vertebrates, called CCPG1. By studying CCPG1 function in the autophagy pathway we will shed light on all above issues AND, conversely, provide insight into the physiological function of this molecule.
Specifically, we will use cell biological and biochemical techniques, including time-resolved correlative light electron microscopy to analyse CCPG1 recruitment from the ER into autophagosomes, and the mechanism thereof, via novel interactions with LC3 and FIP200 that will be separated by mutational analysis. We will show that CCPG1 interacting with FIP200 at autophagic membranes (where these molecules are brought together) participates in a novel mode of regulation of autophagy - the dissociation/inhibition of local ULK complex assemblies. To study this occuring in situ, on autophagic membranes, we will use advanced light microscopic techniques (3D-SIM and FRET acceptor photobleaching). Finally, we will use CCPG1 inhibition (RNAi and a new knockout mouse) to study the physiological role of CCPG1 in fasting, infection and ageing/proteostasis.
Progress has been made unpicking the 'core' mechanism of autophagy. However, regulatory pathways are less well defined; particularly specific negative regulators. Other outstanding questions include a) the regulation of a protein complex called ULK (includes the scaffold, FIP200, and ULK protein kinase) and b) understanding how a site for autophagosome generation, the ER-localised omegasome, can specify the composition of autophagosomes. Here we propose a new negative regulator of autophagy, a little-studied single-pass transmembrane protein, specific to vertebrates, called CCPG1. By studying CCPG1 function in the autophagy pathway we will shed light on all above issues AND, conversely, provide insight into the physiological function of this molecule.
Specifically, we will use cell biological and biochemical techniques, including time-resolved correlative light electron microscopy to analyse CCPG1 recruitment from the ER into autophagosomes, and the mechanism thereof, via novel interactions with LC3 and FIP200 that will be separated by mutational analysis. We will show that CCPG1 interacting with FIP200 at autophagic membranes (where these molecules are brought together) participates in a novel mode of regulation of autophagy - the dissociation/inhibition of local ULK complex assemblies. To study this occuring in situ, on autophagic membranes, we will use advanced light microscopic techniques (3D-SIM and FRET acceptor photobleaching). Finally, we will use CCPG1 inhibition (RNAi and a new knockout mouse) to study the physiological role of CCPG1 in fasting, infection and ageing/proteostasis.
Planned Impact
Beneficiaries of this work beyond immediate colleagues will include (this is just a summary - see Pathways to Impact for how this will be practically achieved/more tangible details):
1) wider bioscience at University of Edinburgh and Bristol, whose knowledge base will be greatly expanded by the use of specialist facilities there (EM, super-resolution microscopy, LC-MS) to address novel and fundamental biological questions. This will raise awareness of the uses, applicability and practicality of such techniques, supported by specific methodological seminars that will be delivered by the PDRA.
2) human and animal health and quality of life via insight into a process important in homoeostasis, ageing and infection, which, in the medium-long term will be built into models developed by these research communities.
3) internationally, the autophagy, general bioscience and animal and human health research communities, by traditional dissemination of new results that impact on our understanding of autophagy and key aspects of organismal homeostasis, and demonstration of new techniques/approaches (e.g. advanced light microscopy) to carry out such investigations.
4) internationally, the fields of infection research, metabolomics and advanced light microscopy, by demonstration of how these techniques can be brought to bear upon a distinct problem from another field, that of new molecule discovery in a fundamental biological pathway to autophagy - to this end we have selected collaborators in each of these fields who have helped shaped the proposal, in particular the cross-disciplinary elements that the collaborations address, and whose own laboratories and work we expect to mutually benefit from these collaborations.
5) UK economy directly and the finances of the University of Edinburgh, via potential commercialisation of CCPG1 reagents, including novel antisera, which will be licensed for use.
6) the UK biomedical industry via potential investigation of CCPG1 as a target for regulating autophagy, leading potentially to programs to develop new agents.
7) the UK science sectors broadly (academic or industry) which will benefit from exceptionally broad training of the PDRA across multi-disciplinary techniques and in other transferable skills such as writing, public engagement and scientific presentation, and including adoption of the role of visiting worker in another institution by the PDRA (from the prinicipal applicant's lab to the coapplicants' labs), further broadening their horizons and organisational/collaborative skills.
8) public understanding of science, particularly how fundamental biological research leads to improvements in health and quality of life for animals and humans, and how this is supported by research council funding. This will be achieved via the dissemination of the work through media channels and by targeted public engagement/science communication activities.
1) wider bioscience at University of Edinburgh and Bristol, whose knowledge base will be greatly expanded by the use of specialist facilities there (EM, super-resolution microscopy, LC-MS) to address novel and fundamental biological questions. This will raise awareness of the uses, applicability and practicality of such techniques, supported by specific methodological seminars that will be delivered by the PDRA.
2) human and animal health and quality of life via insight into a process important in homoeostasis, ageing and infection, which, in the medium-long term will be built into models developed by these research communities.
3) internationally, the autophagy, general bioscience and animal and human health research communities, by traditional dissemination of new results that impact on our understanding of autophagy and key aspects of organismal homeostasis, and demonstration of new techniques/approaches (e.g. advanced light microscopy) to carry out such investigations.
4) internationally, the fields of infection research, metabolomics and advanced light microscopy, by demonstration of how these techniques can be brought to bear upon a distinct problem from another field, that of new molecule discovery in a fundamental biological pathway to autophagy - to this end we have selected collaborators in each of these fields who have helped shaped the proposal, in particular the cross-disciplinary elements that the collaborations address, and whose own laboratories and work we expect to mutually benefit from these collaborations.
5) UK economy directly and the finances of the University of Edinburgh, via potential commercialisation of CCPG1 reagents, including novel antisera, which will be licensed for use.
6) the UK biomedical industry via potential investigation of CCPG1 as a target for regulating autophagy, leading potentially to programs to develop new agents.
7) the UK science sectors broadly (academic or industry) which will benefit from exceptionally broad training of the PDRA across multi-disciplinary techniques and in other transferable skills such as writing, public engagement and scientific presentation, and including adoption of the role of visiting worker in another institution by the PDRA (from the prinicipal applicant's lab to the coapplicants' labs), further broadening their horizons and organisational/collaborative skills.
8) public understanding of science, particularly how fundamental biological research leads to improvements in health and quality of life for animals and humans, and how this is supported by research council funding. This will be achieved via the dissemination of the work through media channels and by targeted public engagement/science communication activities.
Publications
Wilkinson S
(2019)
Picky Eating at the ER-phagy Buffet.
in Trends in biochemical sciences
Wilkinson S
(2020)
Emerging Principles of Selective ER Autophagy.
in Journal of molecular biology
Smith MD
(2018)
CCPG1 Is a Non-canonical Autophagy Cargo Receptor Essential for ER-Phagy and Pancreatic ER Proteostasis.
in Developmental cell
Smith MD
(2018)
CCPG1, a cargo receptor required for reticulophagy and endoplasmic reticulum proteostasis.
in Autophagy
Smith MD
(2018)
CCPG1, an unconventional cargo receptor for ER-phagy, maintains pancreatic acinar cell health.
in Molecular & cellular oncology
Smith M
(2017)
ER homeostasis and autophagy.
in Essays in biochemistry
Smith M
(2022)
Analysis of Pancreatic Acinar Protein Solubility in Autophagy-Deficient Mice.
in Methods in molecular biology (Clifton, N.J.)
Klionsky DJ
(2016)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
in Autophagy
Eck F
(2020)
ACSL3 is a novel GABARAPL2 interactor that links ufmylation and lipid droplet biogenesis.
in Journal of cell science
Description | Autophagy is the process by which cells "keep fit" by binning and recycling their old and damaged components. This process is hugely important for healthy ageing, so it is no surprise that the discovery of its mechanisms was honoured by the 2016 Nobel Prize in Physiology or Medicine. There is also accumulating evidence that autophagy plays important role in cancer and our scientists are heavily involved in cancer-related autophagy research. In a recent study entitled "CCPG1 Is a Non-canonical Autophagy Cargo Receptor Essential for ER-Phagy and Pancreatic ER Proteostasis", published in the journal Developmental Cell, a team led by Dr Simon Wilkinson from the Cancer Research UK Edinburgh Centre revealed that cell-cycle progression gene 1 (CCPG1) plays important role in selective autophagy of the endoplasmic reticulum (known as ER-phagy). The team discovered that CCPG1 protects the digestive-enzyme producing cells of the pancreas from becoming stressed and dying off during ageing, preventing inflammation of the pancreas. Ccpg1 fulfils this role by producing a "caretaker" protein that acts to package up and dispose of damaged bits of the endoplasmic reticulum (ER), the manufacturing centre for digestive enzymes in pancreatic cells. These interesting findings might have implications for healthy ageing and cancer susceptibility and ongoing work in the laboratory aims to address this in detail. |
Exploitation Route | By manipulating levels or function of CCPG1 or as-yet-to-be-discovered interacting proteins, one might envisage preventing pancreatitis and pancreatic cancer formation. |
Sectors | Healthcare |
Title | CCPG1 genetrap mouse |
Description | A transgenic mouse in which the Ccpg1 gene is gene-trapped, generating a hypomorphic animal that has a pancreatic phenotype associated with reduced ER homeostasis. |
Type Of Material | Model of mechanisms or symptoms - mammalian in vivo |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | Currently, academic impact from understanding of the role of CCPG1 protein in healthy ageing of the pancreas. |
Description | Mass spectrometry of autophagy networks |
Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
Country | Germany |
Sector | Academic/University |
PI Contribution | We investigate autophagy protein-protein interaction networks in cancer. |
Collaborator Contribution | Our collaborators (Christian Behrends lab) have provided cutting edge mass spectrometry expertise to analyse samples generated by our lab. This has contributed to a number of publications from the lab. |
Impact | doi.org/10.1016/j.devcel.2017.11.024 doi: 10.1242/jcs.243477 10.4161/auto.29640 doi.org/10.1038/s41467-017-00859-z |
Start Year | 2012 |
Description | Comment to media on 2016 Nobel Prize for Physiology and Medicine |
Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Media (as a channel to the public) |
Results and Impact | Media Interview with journalist from AFP to discuss the significance of the 2016 Nobel Prize for Physiology and Medicine, awarded for discovery of the molecular mechanisms of autophagy. Worldwide, article in various media outlets. In UK, article picked up for Daily Mail (see URL below). |
Year(s) Of Engagement Activity | 2016 |
URL | http://www.dailymail.co.uk/wires/afp/article-3820140/Cells-garbage-disposal-hold-key-healthier-life.... |
Description | I'm a Scientist Get Me Out of Here competition |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Schools |
Results and Impact | Matthew Smith who was hired and trained in lab on the BBSRC grant won the National "I'm a Scientist Get Me Out of Here" Competition in which he had a number of web-based discourses with school pupils about this work. |
Year(s) Of Engagement Activity | 2019 |